IRONWOOD PHARMACEUTICALS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Ironwood Pharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q2 2024.
  • Ironwood Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$860K, a 99.9% increase year-over-year.
  • Ironwood Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was $9.21M.
  • Ironwood Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$1B, a 672% decline from 2022.
  • Ironwood Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was $175M, a 66.9% decline from 2021.
  • Ironwood Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was $528M, a 398% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $9.21M -$860K +$1.06B +99.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$1.05B -$4.16M -$49.9M -109% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$1B -$1.09M -$50M -102% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-16
Q3 2023 -$952M $15.3M -$35M -69.6% Jul 1, 2023 Sep 30, 2023 10-K 2024-02-16
Q2 2023 -$917M -$1.06B -$1.1B -2965% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $182M $45.7M +$6.91M +17.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $175M $48.9M +$7.49M +18.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-16
Q3 2022 $168M $50.3M -$5.53M -9.9% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-16
Q2 2022 $173M $37.1M -$354M -90.5% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-16
Q1 2022 $527M $38.8M -$1.13M -2.82% Jan 1, 2022 Mar 31, 2022 10-K 2024-02-16
Q4 2021 $528M $41.4M -$1.83M -4.24% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-16
Q3 2021 $530M $55.8M +$21.4M +62.2% Jul 1, 2021 Sep 30, 2021 10-K 2023-02-16
Q2 2021 $509M $391M +$366M +1453% Apr 1, 2021 Jun 30, 2021 10-K 2023-02-16
Q1 2021 $143M $39.9M +$36.6M +1094% Jan 1, 2021 Mar 31, 2021 10-K 2023-02-16
Q4 2020 $106M $43.2M -$4.65M -9.73% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-18
Q3 2020 $111M $34.4M +$13.8M +66.7% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-18
Q2 2020 $97.1M $25.2M +$12.9M +105% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-18
Q1 2020 $84.1M $3.35M +$62.6M Jan 1, 2020 Mar 31, 2020 10-K 2022-02-18
Q4 2019 $21.5M $47.9M +$63.4M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-17
Q3 2019 -$41.8M $20.6M +$195M Jul 1, 2019 Sep 30, 2019 10-K 2021-02-17
Q2 2019 -$237M $12.3M +$61.7M Apr 1, 2019 Jun 30, 2019 10-K 2021-02-17
Q1 2019 -$299M -$59.3M -$16.1M -37.4% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-17
Q4 2018 -$282M -$15.5M -$27.6M -228% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 -$255M -$174M -$142M -440% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 -$113M -$49.4M -$5.16M -11.7% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 -$108M -$43.1M +$9.36M +17.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 -$117M $12.1M +$25.6M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-25
Q3 2017 -$143M -$32.3M +$907K +2.73% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-25
Q2 2017 -$143M -$44.2M -$22.5M -104% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-25
Q1 2017 -$121M -$52.5M -$39.2M -295% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-25
Q4 2016 -$81.7M -$13.5M Oct 1, 2016 Dec 31, 2016 10-K 2018-02-22
Q3 2016 -$33.2M Jul 1, 2016 Sep 30, 2016 10-K 2018-02-22
Q2 2016 -$21.7M Apr 1, 2016 Jun 30, 2016 10-K 2018-02-22
Q1 2016 -$13.3M Jan 1, 2016 Mar 31, 2016 10-K 2018-02-22
Q2 2011 -$18.8M -$1.71M -9.97% Apr 1, 2011 Jun 30, 2011 10-Q 2011-08-12
Q2 2010 -$17.1M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.